secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2026-07-24T20:05:14+00:00
Accession:  0001193125-26-316067
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics receives Nasdaq delisting notice for bid price non-compliance
----------------------------------------------------------------------------

- Nasdaq Staff Determination on July 22, 2026: bid price below $1.00 for 30 consecutive business days (June 8–July 21, 2026).
- Company ineligible for 180-day cure period due to reverse stock split within prior year (Listing Rule 5810(c)(3)(A)(iv)).
- Delisting scheduled for July 31, 2026 unless appeal requested by July 29, 2026; company intends to request hearing.
- At hearing, company will present plan to regain compliance; no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526316067/0001193125-26-316067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526316067/fblg-20260722.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-316067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer